Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis.

Nazli DizmanYung LyouNicholas SalgiaPaulo Gustavo BergerotJoAnn HsuDaniel EnriquezTyler IzattJeffrey M TrentSara ByronSumanta Pal

Published in: Journal for immunotherapy of cancer (2021)

Our analysis found that TERT promoter mutations may be a negative predictor of outcome with IO and are mutually exclusive with PBRM1 loss-of-function mutations.

Keyphrases

metastatic renal cell carcinoma
dna methylation
gene expression
transcription factor
copy number
genome wide
data analysis